{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastric+Neuroendocrine+Carcinoma&page=2",
    "query": {
      "condition": "Gastric Neuroendocrine Carcinoma",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastric+Neuroendocrine+Carcinoma&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-26T01:12:45.827Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03896958",
      "title": "The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cancer, All Types",
        "Cancer of Liver",
        "Cancer of Stomach",
        "Cancer of Head and Neck",
        "Cancer of Rectum",
        "Cancer of Kidney",
        "Cancer of Esophagus",
        "Cancer of Colon",
        "Cancer Skin",
        "Cancer of Cervix",
        "Cancer, Metastatic",
        "Cancer of Larynx",
        "Cancer of Neck",
        "Cancer of Lung",
        "Cancer of Brain and Nervous System",
        "Cancer of Vulva, Disseminated",
        "Cancer of Pancreas",
        "Sarcoma",
        "GIST",
        "Small-cell Lung Cancer",
        "Adenocarcinoma Lung",
        "Cancer of Prostate",
        "Cancer, Advanced",
        "Adrenal Cancer",
        "Testicular Cancer",
        "Uterine Cancer",
        "Bronchoalveolar Cell Lung Cancer",
        "Cancer Unknown Primary",
        "Glioblastoma Multiforme",
        "Oligodendroglioma",
        "Breast Cancer",
        "Renal Cell Carcinoma",
        "Hepatocellular Carcinoma",
        "Cholangiocarcinoma",
        "Squamous Cell Carcinoma",
        "Transitional Cell Carcinoma",
        "Cancer, Other",
        "Cancer, Anal",
        "Melanoma",
        "Cancer, Bile Duct",
        "Cancer, Bladder",
        "Cancer Cords Vocal",
        "Cancers Cell Neuroendocrine",
        "Cancer Differentiated Poorly",
        "Cancer, Anaplastic Thyroid"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "SpeciCare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "1 Month to 99 Years"
      },
      "enrollment_count": 1000,
      "start_date": "2019-03-21",
      "completion_date": "2024-03-12",
      "has_results": false,
      "last_update_posted_date": "2020-12-04",
      "last_synced_at": "2026-06-26T01:12:45.827Z",
      "location_count": 1,
      "location_summary": "Gainesville, Georgia",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03896958"
    },
    {
      "nct_id": "NCT00049296",
      "title": "Thalidomide and Docetaxel in Treating Patients With Advanced Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "docetaxel",
          "type": "DRUG"
        },
        {
          "name": "thalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2002-07",
      "completion_date": "2006-01",
      "has_results": false,
      "last_update_posted_date": "2010-06-11",
      "last_synced_at": "2026-06-26T01:12:45.827Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00049296"
    },
    {
      "nct_id": "NCT00428220",
      "title": "A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Metastatic Breast Cancer",
        "Advanced Breast Cancer",
        "Metastatic Castration Resistant Prostate Cancer",
        "Metastatic Renal Cell Cancer",
        "Non-Small Cell Lung Cancer",
        "Thyroid Cancer",
        "Advanced/Metastatic Non-Small Cell Lung Cancer",
        "Advanced Gastric Cancer",
        "Gastrointestinal Stromal Tumor",
        "Hepatocellular Carcinoma",
        "Pancreatic Islet Cell Carcinoma",
        "Pancreatic Neuroendocrine Tumor"
      ],
      "interventions": [
        {
          "name": "sunitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 223,
      "start_date": "2007-07",
      "completion_date": "2014-09",
      "has_results": true,
      "last_update_posted_date": "2019-06-27",
      "last_synced_at": "2026-06-26T01:12:45.827Z",
      "location_count": 15,
      "location_summary": "Atlanta, Georgia • Maywood, Illinois • Iowa City, Iowa + 7 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Maywood",
          "state": "Illinois"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00428220"
    },
    {
      "nct_id": "NCT05477576",
      "title": "Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "GEP-NET",
        "Gastroenteropancreatic Neuroendocrine Tumor",
        "Gastroenteropancreatic Neuroendocrine Tumor Disease",
        "Neuroendocrine Tumors",
        "Carcinoid",
        "Carcinoid Tumor",
        "Pancreatic NET"
      ],
      "interventions": [
        {
          "name": "RYZ101",
          "type": "DRUG"
        },
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "Sunitinib",
          "type": "DRUG"
        },
        {
          "name": "Octreotide",
          "type": "DRUG"
        },
        {
          "name": "Lanreotide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "RayzeBio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 338,
      "start_date": "2022-03-24",
      "completion_date": "2030-12",
      "has_results": false,
      "last_update_posted_date": "2026-03-30",
      "last_synced_at": "2026-06-26T01:12:45.827Z",
      "location_count": 32,
      "location_summary": "Phoenix, Arizona • Duarte, California • Irvine, California + 27 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05477576"
    },
    {
      "nct_id": "NCT04579757",
      "title": "Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Solid Tumor",
        "Colorectal Cancer",
        "Neuroendocrine Tumors",
        "Small Cell Lung Cancer",
        "Gastric Cancer",
        "Soft Tissue Sarcoma",
        "Anaplastic Thyroid Cancer"
      ],
      "interventions": [
        {
          "name": "Surufatinib and Tislelizumab _ Part 1",
          "type": "DRUG"
        },
        {
          "name": "Surufatinib and Tislelizumab _ Part 2",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hutchmed",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 87,
      "start_date": "2021-03-05",
      "completion_date": "2024-08-27",
      "has_results": true,
      "last_update_posted_date": "2025-05-08",
      "last_synced_at": "2026-06-26T01:12:45.827Z",
      "location_count": 18,
      "location_summary": "Tucson, Arizona • Duarte, California • Denver, Colorado + 13 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04579757"
    },
    {
      "nct_id": "NCT00014456",
      "title": "Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Bladder Cancer",
        "Breast Cancer",
        "Carcinoma of Unknown Primary",
        "Esophageal Cancer",
        "Gastric Cancer",
        "Head and Neck Cancer",
        "Lung Cancer",
        "Melanoma (Skin)",
        "Ovarian Cancer",
        "Pancreatic Cancer",
        "Prostate Cancer",
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "docetaxel",
          "type": "DRUG"
        },
        {
          "name": "gemcitabine hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Dartmouth-Hitchcock Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2000-03",
      "completion_date": "2005-10",
      "has_results": false,
      "last_update_posted_date": "2013-08-28",
      "last_synced_at": "2026-06-26T01:12:45.827Z",
      "location_count": 1,
      "location_summary": "Lebanon, New Hampshire",
      "locations": [
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00014456"
    },
    {
      "nct_id": "NCT05461430",
      "title": "Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Pleural Effusion, Malignant",
        "Ascites, Malignant",
        "Carcinoma",
        "Carcinoma, Hepatocellular",
        "Carcinoma, Renal Cell",
        "Carcinoma, Renal",
        "Carcinoma, Small Cell",
        "Carcinoma, Non-Small-Cell Lung",
        "Carcinoma, Pancreatic Ductal",
        "Carcinoma, Neuroendocrine",
        "Carcinoma, Thymic",
        "Carcinoma, Pancreatic",
        "Carcinoma Breast",
        "Carcinoma, Ovarian",
        "Carcinoma Bladder",
        "Carcinoma of Unknown Primary",
        "Carcinoma of the Head and Neck",
        "Carcinoma of the Oropharynx",
        "Carcinoma of the Larynx",
        "Carcinoma of the Bladder",
        "Carcinoma of Esophagus",
        "Carcinoma of the Nasopharynx",
        "Carcinoma of the Penis",
        "Carcinoma of the Cervix",
        "Carcinoma of the Anus",
        "Carcinoma of the Vulva",
        "Carcinoma of the Appendix",
        "Carcinoma of the Oral Cavity",
        "Cholangiocarcinoma",
        "Melanoma",
        "Mesothelioma",
        "Pancreatic Cancer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Travera Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2022-07-15",
      "completion_date": "2026-03-23",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-06-26T01:12:45.827Z",
      "location_count": 1,
      "location_summary": "Oakland, California",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05461430"
    },
    {
      "nct_id": "NCT06910657",
      "title": "IDOV-Immune for Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Colorectal Cancer",
        "Pancreatic Cancer",
        "Melanoma",
        "Ovarian Cancer",
        "Gastric Cancer",
        "Esophageal Cancer",
        "Hepatocellular Carcinoma",
        "Renal Cell Carcinoma",
        "Breast Cancer",
        "Sarcoma",
        "Bladder Cancer",
        "Lung Cancer",
        "Prostate Cancer",
        "Cervical Cancers",
        "Head and Neck Cancers",
        "Adrenal Gland Tumors"
      ],
      "interventions": [
        {
          "name": "IDOV-Immune (oncolytic vaccinia virus)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ViroMissile, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 78,
      "start_date": "2025-08-25",
      "completion_date": "2027-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-02",
      "last_synced_at": "2026-06-26T01:12:45.827Z",
      "location_count": 3,
      "location_summary": "St Louis, Missouri • Houston, Texas • San Antonio, Texas",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06910657"
    },
    {
      "nct_id": "NCT06131398",
      "title": "A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "AMG 355",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 77,
      "start_date": "2024-03-07",
      "completion_date": "2026-07-21",
      "has_results": false,
      "last_update_posted_date": "2026-05-28",
      "last_synced_at": "2026-06-26T01:12:45.827Z",
      "location_count": 6,
      "location_summary": "Duarte, California • Merriam, Kansas • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Merriam",
          "state": "Kansas"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06131398"
    },
    {
      "nct_id": "NCT05064150",
      "title": "Neuroendocrine Tumors - Patient Reported Outcomes",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Neuroendocrine Tumors",
        "Gastroenteropancreatic Neuroendocrine Tumor",
        "Lung Neuroendocrine Neoplasm",
        "Neuroendocrine Carcinoma"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Iowa",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2539,
      "start_date": "2022-05-10",
      "completion_date": "2026-06",
      "has_results": false,
      "last_update_posted_date": "2025-12-18",
      "last_synced_at": "2026-06-26T01:12:45.827Z",
      "location_count": 14,
      "location_summary": "Gainesville, Florida • Iowa City, Iowa • Kansas City, Kansas + 11 more",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05064150"
    }
  ]
}